annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
Brd. 8F Evaluation of poxviruses targeting the tumor microenvironment for cancer
therapy. (Abstract #2600)
D. Kim, S. Kim-Schulze, G. Deraffele, J. Schlom, H. Kaufman
Brd. 8G A comparison of the Cockroft-Gault (CG) and the modification of diet in renal
disease (MDRD) equations for estimating renal function and guiding dose
adjustment of oncology-related drugs. (Abstract #2601)
J. A. Grillo, S. Abraham, A. Khandelwal, Q. Liu, B. Booth, N. A. Rahman
Brd. 8H A phase I study of prolonged infusion of triapine in combination with a
fixed-dose rate of gemcitabine in patients with advanced solid tumors.
(Abstract #2602)
A. Mortazavi, D. Deam, Y. Ling, E. J. Harper, M. A. Phelps, I. J. Espinoza-Delgado,
J. P. Monk III, G. A. Otterson, M. R. Grever, T. Bekaii-Saab
Brd. 9A Phase I study of proteasome inhibitor bortezomib (B) concurrent with
re-irradiation therapy (re-RT) for recurrent squamous cell carcinoma of the
head and neck (SCCHN). (Abstract #2603)
J. C. Morris, D. E. Citrin, L. Nottingham, S. F. Rudy, N. Harold, T. Cooley-Zgela,
D. Goldstein, J. J. Wright, B. A. Conley, C. Van Waes
Brd. 9B Toxicity in 1,181 patients with advanced solid tumors treated in phase I
clinical trials of predominantly targeted agents: The M. D. Anderson Cancer
Center experience. (Abstract #2604)
J. J. Wheler, A. M. Tsimberidou, S. Wen, A. Naing, D. S. Hong, G. S. Falchook,
S. A. Piha-Paul, S. Fu, S. L. Moulder, R. Kurzrock, Toxicity Working Group
Brd. 9C A phase I study of ABT-888 (A) in combination with metronomic
cyclophosphamide (C) in adults with refractory solid tumors and
lymphomas. (Abstract #2605)
S. Kummar, A. P. Chen, J. J. Ji, D. Allen, M. J. Egorin, D. R. Gandara, H. Lenz,
R. Morgan, E. M. Newman, J. H. Doroshow
Brd. 9D Single-nucleotide polymorphisms (SNPs) of CYP19A1 and plasma levels of
estrone sulfate (ES) in postmenopausal women with breast cancer (BC)
during letrozole (L) treatment. (Abstract #2606)
G. Lunardi, S. Lastraioli, P. Bruzzi, P. Pronzato, G. Bisagni, R. Ponzone, M.
Porpiglia, S. Russo, L. Del Mastro, M. Venturini, Gruppo Italiano Mammella (GIM)
Brd. 9E Phase I pharmacokinetic and safety analysis of epothilone folate (BMS-
753493): First-in-human clinical experience of a folate receptor-targeted
chemotherapeutic agent administered on days 1, 4, 8, and 11 of a 21-day
cycle. (Abstract #2607)
M. J. De Jonge, S. Sleijfer, L. P. Martin, J. Marshall, J. F. Deeken, J. A. Konner, C.
Aghajanian, BMS Phase I Clinical Research Team
Brd. 9F Bystander vaccine therapy in mantle cell lymphoma (MCL): Phase II clinical
results. (Abstract #2608)
B. D. Shah, J. Tao, L. Sokol, P. A. Chervenick, M. R. Tomblyn, J. Pinilla-Ibarz,
L. Moscinski, S. Antonia, E. M. Sotomayor, S. Dessureault
Brd. 9G Evaluation of baseline serum C-reactive protein (CRP) and benefit from
tremelimumab compared to chemotherapy in first-line melanoma.
(Abstract #2609)
M. A. Marshall, A. Ribas, B. Huang
Brd. 9H Phase I trial of dasatinib (D) and lapatinib (L). (Abstract #2610)
C. Erlichman, M. E. Menefee, D. W. Northfelt, R. Qin, J. M. Reid, M. Oursler,
R. Marks, P. Haluska, J. R. Molina, K. Koch
Brd. 10A Trabedersen (AP 12009) in the treatment of patients with advanced tumors:
Completion of dose-escalation and first efficacy data. (Abstract #2611)
H. Oettle, A. Hilbig, T. Seufferlein, T. Luger, R. M. Schmid, G. von Wichert,
S. Schmaus, H. Heinrichs, K. Schlingensiepen
Brd. 10B Phase I, dose-escalation study of BIIB022 (anti-IGF-1R antibody) in advanced
solid tumors. (Abstract #2612)
M. von Mehren, C. Britten, K. Lear, D. R. Camidge, Z. A. Wainberg, P. C. Pieslor,
M. Darif, S. Harris, K. Balogh, S. Leong
306